1
|
Duboscq C, Sueldo E, Rosa C, Zirpoli M, Ceresetto J, Baques A, Arias M. High variability in Factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system. Int J Lab Hematol 2024; 46:128-134. [PMID: 37704365 DOI: 10.1111/ijlh.14171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 08/30/2023] [Indexed: 09/15/2023]
Abstract
INTRODUCTION Haemophilia B (HB) is an X-linked hereditary bleeding disorder characterized by coagulation factor IX (FIX) deficiency. To improve the quality of life of patients and adherence to treatment, recombinant factor concentrates modified to extend their half-life have been developed, called extended half-life factors (EHL: extended half-life). Nonacog beta pegol (N9-GP) is a glycopegylated recombinant human FIX molecule that has a half-life of 93 h with a single dose and has shown a higher recovery percentage than other molecules. To diagnose and monitor the treatment of haemophiliac patients, FIX activity is determined with the one-stage clotting assay (OSA) and/or the chromogenic assay. The objective of this work, carried out in three centres, was to measure the recovery of N9-PG with 10 different activated partial thromboplastin time (APTT) reagents on three platforms, in samples spiked in vitro with N9-GP, at four different concentration levels. METHODS It was measured the recovery of N9-GP with 10 different APTT reagents (polyphenol, ellagic acid, silice dioxide, colloidal silica as APTT activator on three platforms, in sample spiked in vitro with N9-GP. RESULTS The results show heterogeneity in the activity of N9-GP measured by OSA with the different APTT reagents when the calibrations were performed with the specific calibrator of each coagulometer. A recovery percentage between 87% and 108% was obtained only with polyphenol and ellagic acid as activator in the three platforms evaluated. The other reagents studied overestimate or underestimate, with no clear profile. When a calibration curve was performed with a calibrator prepared from the N9-GP vial, all APTT reagents met the established recovery requirement. CONCLUSION APTT reagents with polyphenol or ellagic acid as activator would be the only ones appropriate when using the commercially available OSA with specific calibrator to monitor patients treated with N9-GP.
Collapse
Affiliation(s)
- C Duboscq
- Servicio Hematología, Hospital Británico, Buenos Aires, Argentina
| | - E Sueldo
- Laboratorio de Hematología Y Hemostasia, Hospital Dr. César Milstein, Buenos Aires, Argentina
| | - C Rosa
- Laboratorio Central Hospital, Hospital Universitario Austral, Buenos Aires, Argentina
| | - M Zirpoli
- Laboratorio Central Hospital, Hospital Universitario Austral, Buenos Aires, Argentina
| | - J Ceresetto
- Servicio Hematología, Hospital Británico, Buenos Aires, Argentina
| | - A Baques
- Servicio de Hemofilia, Dr. César Milstein, Buenos Aires, Argentina
| | - M Arias
- Laboratorio de Hematología Y Hemostasia, Hospital Dr. César Milstein, Buenos Aires, Argentina
| |
Collapse
|
2
|
Ojeda A, Calvo A, Cuñat T, Mellado-Artigas R, Costas-Carrera A, Sánchez-Rodriguez MM, Comino-Trinidad O, Aliaga J, Arias M, Martínez-Pallí G, Dürsteler C, Ferrando C. Effectiveness of a specific follow up program for the management of the mental components of post-intensive care syndrome and chronic pain after COVID-19: results from the PAIN-COVID randomized clinical trial. Rev Esp Anestesiol Reanim (Engl Ed) 2024:S2341-1929(23)00206-8. [PMID: 38242358 DOI: 10.1016/j.redare.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 05/11/2023] [Indexed: 01/21/2024]
Abstract
BACKGROUND Critical COVID-19 survivors are at risk of developing Post-intensive Care Syndrome (PICS) and Chronic ICU-Related Pain (CIRP). We determined whether a specific care program improves the quality of life (QoL) of patients at risk of developing PICS and CIRP after COVID-19. METHODS The PAIN-COVID trial was a parallel-group, single-centre, single-blinded, randomized controlled trial. The intervention consisted of a follow up program, patient education on PICS and pain, and a psychological intervention based on Rehm's self-control model in patients with abnormal depression scores (≥8) in the Hospital Anxiety and Depression Scale (HADS) at the baseline visit. QoL was evaluated with the 5-level EQ 5D (EQ 5D 5 L), mood disorders with the HADS, post-traumatic stress disorder (PTSD) with the PCL-5 checklist, and pain with the Brief Pain Inventory short form, the Douleur Neuropathique 4 questionnaire, and the Pain Catastrophizing Scale. The primary outcome was to determine if the program was superior to standard-of-care on the EQ visual analogue scale (VAS) at 6 months after the baseline visit. The secondary outcomes were EQ VAS at 3 months, and EQ index, CIRP incidence and characteristics, and anxiety, depression, and PTSD at 3 and 6 months after baseline visits. CONCLUSIONS This program was not superior to standard care in improving QoL in critical COVID-19 survivors as measured by the EQ VAS. However, our data can help establish better strategies for the study and management of PICS and CIRP in this population. TRIAL REGISTRATION # NCT04394169, registered on 5/19/2020.
Collapse
Affiliation(s)
- A Ojeda
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
| | - A Calvo
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - T Cuñat
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | - R Mellado-Artigas
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | - A Costas-Carrera
- Neuroscience Institute, Hospital ClÍnic, University of Barcelona, Barcelona, Spain
| | | | - O Comino-Trinidad
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | - J Aliaga
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | - M Arias
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | - G Martínez-Pallí
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| | - C Dürsteler
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Department of Surgery and Surgical Specializations, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain
| | - C Ferrando
- Department of Anesthesiology, Critical Care and Pain Medicine, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
3
|
Fuentes F, Águila L, Arias M, Felmer R. 139 Exogenous activation of bovine oocytes after piezo-intracytoplasmic sperm injection: is it really necessary? Reprod Fertil Dev 2022. [DOI: 10.1071/rdv35n2ab139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
4
|
Arias M, Mir P, Fernández-Matarrubia M, Arpa J, García-Ramos R, Blanco-Arias P, Quintans B, Sobrido MJ. Autosomal recessive spinocerebellar ataxia SCAR8/ARCA1: first families detected in Spain. Neurologia (Engl Ed) 2022; 37:257-262. [PMID: 35595401 DOI: 10.1016/j.nrleng.2019.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 01/16/2019] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Autosomal recessive spinocerebellar ataxia type 8 (ARCA1/SCAR8) is caused by mutations of the SYNE1 gene. The disease was initially described in families from Quebec (Canada) with a phenotype of pure cerebellar syndrome, but in recent years has been reported with a more variable clinical phenotype in other countries. Cases have recently been described of muscular dystrophy, arthrogryposis, and cardiomyopathy due to SYNE1 mutations. OBJECTIVE To describe clinical and molecular findings from 4 patients (3 men and one woman) diagnosed with ARCA1/SCAR8 from 3 Spanish families from different regions. MATERIAL AND METHODS We describe the clinical, paraclinical, and genetic results from 4 patients diagnosed with ARCA1/SCAR8 at different Spanish neurology departments. RESULTS Onset occurred in the third or fourth decade of life in all patients. After 15 years of progression, 3 patients presented pure cerebellar syndrome, similar to the Canadian patients; the fourth patient, with over 30 years' progression, presented vertical gaze palsy, pyramidal signs, and moderate cognitive impairment. In all patients, MRI studies showed cerebellar atrophy. The genetic study revealed distinct pathogenic SYNE1 mutations in each family. CONCLUSIONS ARCA1/SCAR8 can be found worldwide and may be caused by many distinct mutations in the SYNE1 gene. The disease may manifest with a complex phenotype of varying severity.
Collapse
Affiliation(s)
- M Arias
- Servicio de Neurología, Complexo Hospitalario de Santiago de Compostela, Santiago de Compostela, La Coruña, Spain.
| | - P Mir
- Servicio de Neurología, Hospital Virgen del Rocío, Sevilla, Spain
| | | | - J Arpa
- Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
| | - R García-Ramos
- Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
| | - P Blanco-Arias
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, La Coruña, Spain
| | - B Quintans
- Grupo de Neurogenética, Instituto de Investigación Sanitaria de Santiago (IDIS)-Complexo Hospitalario Universitario, Santiago de Compostela, La Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - M J Sobrido
- Grupo de Neurogenética, Instituto de Investigación Sanitaria de Santiago (IDIS)-Complexo Hospitalario Universitario, Santiago de Compostela, La Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
5
|
Carmina G, Nieto R, Arias M. African Swine Fever Virus (ASFV) Indirect ELISA Test Based on the Use of the Soluble Cytoplasmic Semi- purified Antigen (ASFV CP-Ag). Methods Mol Biol 2022; 2503:133-145. [PMID: 35575891 DOI: 10.1007/978-1-0716-2333-6_9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The present chapter describes a simple and economic indirect enzyme immunoassay (ELISA ) for African swine fever virus (ASFV) antibody detection based on the use of the soluble cytoplasmic fraction of ASFV-infected monkey stable cells (MS). The soluble antigen proteins of ASFV-infected cells are separated by sucrose precipitation centrifugation, and the supernatant above the sucrose layer is used as an ELISA antigen. The test serum sample reacts with the cytoplasmic soluble fraction, and antibodies are detected using a protein A-peroxidase conjugate. This crude antigen is currently recommended as a test reagent in screening and diagnostic tests by the World Organization for Animal Health (OIE).
Collapse
Affiliation(s)
- Gallardo Carmina
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA-INIA/CSIC, Valdeolmos, Madrid, Spain.
| | - R Nieto
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA-INIA/CSIC, Valdeolmos, Madrid, Spain
| | - M Arias
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA-INIA/CSIC, Valdeolmos, Madrid, Spain
| |
Collapse
|
6
|
Arias M, Mir P, Fernández-Matarrubia M, Arpa J, García-Ramos R, Blanco-Arias P, Quintans B, Sobrido MJ. Autosomal recessive spinocerebellar ataxia SCAR8/ARCA1: First families detected in Spain. Neurologia 2022; 37:257-262. [PMID: 31103315 DOI: 10.1016/j.nrl.2019.01.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 01/16/2019] [Indexed: 12/28/2022] Open
Abstract
INTRODUCTION Autosomal recessive spinocerebellar ataxia type 8 (ARCA1/SCAR8) is caused by mutations of the SYNE1 gene. The disease was initially described in families from Quebec (Canada) with a phenotype of pure cerebellar syndrome, but in recent years has been reported with a more variable clinical phenotype in other countries. Cases have recently been described of muscular dystrophy, arthrogryposis, and cardiomyopathy due to SYNE1 mutations. OBJECTIVE To describe clinical and molecular findings from 4 patients (3 men and one woman) diagnosed with ARCA1/SCAR8 from 3 Spanish families from different regions. MATERIAL AND METHODS We describe the clinical, paraclinical, and genetic results from 4 patients diagnosed with ARCA1/SCAR8 at different Spanish neurology departments. RESULTS Onset occurred in the third or fourth decade of live in all patients. After 15 years of progression, 3 patients presented pure cerebellar syndrome, similar to the Canadian patients; the fourth patient, with over 30 years' progression, presented vertical gaze palsy, pyramidal signs, and moderate cognitive impairment. In all patients, MRI studies showed cerebellar atrophy. The genetic study revealed distinct pathogenic SYNE1 mutations in each family. CONCLUSIONS ARCA1/SCAR8 can be found worldwide and may be caused by many distinct mutations in the SYNE1 gene. The disease may manifest with a complex phenotype of varying severity.
Collapse
Affiliation(s)
- M Arias
- Servicio de Neurología, Complexo Hospitalario de Santiago de Compostela, Santiago de Compostela, La Coruña, España.
| | - P Mir
- Servicio de Neurología, Hospital Virgen del Rocío, Sevilla, España
| | | | - J Arpa
- Servicio de Neurología, Hospital Clínico San Carlos de, Madrid, España
| | - R García-Ramos
- Servicio de Neurología, Hospital Clínico San Carlos de, Madrid, España
| | - P Blanco-Arias
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, La Coruña, España
| | - B Quintans
- Grupo de Neurogenética, Instituto de Investigación Sanitaria de Santiago (IDIS)-Complexo Hospitalario Universitario, Santiago de Compostela, La Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, España
| | - M J Sobrido
- Grupo de Neurogenética, Instituto de Investigación Sanitaria de Santiago (IDIS)-Complexo Hospitalario Universitario, Santiago de Compostela, La Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, España
| |
Collapse
|
7
|
Carmina G, Nieto R, Arias M. Indirect Immunoperoxidase Test (IPT) for Detection of Antibodies Against African Swine Fever Virus (ASFV) on African Green Monkey Cell Lines (Vero, MS). Methods Mol Biol 2022; 2503:147-158. [PMID: 35575892 DOI: 10.1007/978-1-0716-2333-6_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The immunoperoxidase technique (IPT) is an immunocytochemistry technique on fixed infected cells to determine the antibody-antigen complex formation through the action of the peroxidase enzyme. In this procedure, African green monkey established cell lines, such as Vero or MS, are infected with African swine fever virus (ASFV)-adapted isolates to these cell cultures. The infected cells are fixed and then used as antigens to determine the presence of the specific antibodies against ASFV in samples of swine origin. IPT has many advantages for the serological diagnosis of ASF. Firstly, IPT has a higher sensitivity than ELISA or immunoblot assay (IB) for the detection of antibodies against ASFV. Secondly, it has greater versatility to analyze any type of clinical sample of porcine origin and to conduct research studies on the epidemiological situation, through the presence of antibody titers in exudates from organs and tissues. Thirdly, the preparation of IPT plates with cells infected with ASFV is simple, although laborious, that can be stored for a long time and allow the analysis of a large number of samples.
Collapse
Affiliation(s)
- Gallardo Carmina
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain.
| | - R Nieto
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain
| | - M Arias
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, Madrid, Spain
| |
Collapse
|
8
|
Del Castillo D, Arroyo G, Escorza J, Angulo Y, Debut A, Vizuete K, Izquierdo A, Arias M. Development of a hybrid cell for energy production. Nanotechnology 2021; 32:415401. [PMID: 34285145 DOI: 10.1088/1361-6528/ac0c3e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 06/17/2021] [Indexed: 06/13/2023]
Abstract
This study focuses on the development of a new hybrid biological material to be applied in the production of electrical energy. These organo-metallic cells are constituted by cyanobacteria (Fischerella muscicola) and silver nanoparticles (AgNPs). AgNPs were obtained by green synthesis using the extract of the fruit of theBerberis halliiplant as reducing agent with two different concentrations of silver nitrate (AgNO3), 1 and 10 mM. The morphology, physicochemical and electrical properties of the cyanobacteria with and without AgNPs were evaluated. To verify the efficacy of this new material, and the effect of the medium used, Nitrofoska or BG-11, the growth kinetics was evaluated by UV-vis up tot= 63 d with and without renewal of the culture medium and O2/CO2exchange. Through morphological characterizations ofFischerella muscicolait was possible to identify the presence of an associated bacterium identified using molecular techniques asPseudomona guguanensithat could act as a supporting organism in the growth of this cyanobacteria. The studies carried out did not shown cell toxicity for the cultures that have AgNPs and on the other hand, it was observed that the hybrid cells (Cy-AgNPs) are electron carriers recording an increase of up to 57% and 18% in their electrical potential with BG-11 and Nitrofoska culture media, respectively and an increase in the anodic current peak of 6.5% of Cy-AgNPs respect to onlyF. musicola.
Collapse
Affiliation(s)
- D Del Castillo
- Carrera de Ingeniería en Biotecnología, Departamento de Ciencias de la Vida, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - G Arroyo
- Centro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - J Escorza
- Maestría de Nanotecnología, Centro de Postgrado, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - Y Angulo
- Centro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - A Debut
- Centro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - K Vizuete
- Centro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - A Izquierdo
- Centro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| | - M Arias
- Centro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, PO BOX 231B, Sangolquí, Ecuador
| |
Collapse
|
9
|
van de Berg SEJ, Pelzer PT, van der Land AJ, Abdrakhmanova E, Ozi AM, Arias M, Cook-Scalise S, Dravniece G, Gebhard A, Juneja S, Handayani R, Kappel D, Kimerling M, Koppelaar I, Malhotra S, Myrzaliev B, Nsa B, Sugiharto J, Engel N, Mulder C, van den Hof S. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients. BMC Public Health 2021; 21:1404. [PMID: 34271884 PMCID: PMC8284025 DOI: 10.1186/s12889-021-11427-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 06/30/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. The objective of this study was to assess the acceptability, feasibility, and likelihood of implementing BPaL in Indonesia, Kyrgyzstan, and Nigeria. METHODS We conducted a concurrent mixed-methods study among a cross-section of health care workers, programmatic and laboratory stakeholders between May 2018 and May 2019. We conducted semi-structured interviews and focus group discussions to assess perceptions on acceptability and feasibility of implementing BPaL. We determined the proportions of a recoded 3-point Likert scale (acceptable; neutral; unacceptable), as well as the overall likelihood of implementing BPaL (likely; neutral; unlikely) that participants graded per regimen, pre-defined aspect and country. We analysed the qualitative results using a deductive framework analysis. RESULTS In total 188 stakeholders participated in this study: 63 from Kyrgyzstan, 51 from Indonesia, and 74 from Nigeria The majority were health care workers (110). Overall, 88% (146/166) of the stakeholders would likely implement BPaL once available. Overall acceptability for BPaL was high, especially patient friendliness was often rated as acceptable (93%, 124/133). In contrast, patient friendliness of the ITR was rated as acceptable by 45%. Stakeholders appreciated that BPaL would reduce workload and financial burden on the health care system. However, several stakeholders expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulatory requirements regarding introduction of the regimen. Stakeholders stressed the importance of addressing current health systems constraints as well, especially in treatment and safety monitoring systems. CONCLUSIONS Acceptability and feasibility of the BPaL regimen is high among TB stakeholders in Indonesia, Kyrgyzstan, and Nigeria. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints.
Collapse
Affiliation(s)
| | - P T Pelzer
- KNCV Tuberculosis foundation, The Hague, The Netherlands.
| | | | | | - A Muhammad Ozi
- National Tuberculosis and Leprosy control Program Nigeria, Mabushi, Nigeria
| | - M Arias
- KNCV Tuberculosis foundation, The Hague, The Netherlands
| | | | - G Dravniece
- KNCV Tuberculosis foundation, The Hague, The Netherlands
- PATH, Kyiv, Ukraine
| | - A Gebhard
- KNCV Tuberculosis foundation, The Hague, The Netherlands
| | | | - R Handayani
- National TB Program Indonesia, Jakarta, Indonesia
| | | | - M Kimerling
- KNCV Tuberculosis foundation, The Hague, The Netherlands
| | - I Koppelaar
- KNCV Tuberculosis foundation, The Hague, The Netherlands
| | | | - B Myrzaliev
- KNCV country office Kyrgyzstan, Bishkek, Kyrgyzstan
| | - B Nsa
- KNCV country office Nigeria, Abuja, Nigeria
| | | | - N Engel
- Maastricht University, Maastricht, The Netherlands
| | - C Mulder
- KNCV Tuberculosis foundation, The Hague, The Netherlands
- Amsterdam Institute for Global Health and Development, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - S van den Hof
- KNCV Tuberculosis foundation, The Hague, The Netherlands
- National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| |
Collapse
|
10
|
Lockhart C, Carboni Bisso I, Potenzoni A, Bertoia N, Arias M, Ceballos IF, Las Heras M. Comment on: 'timing and clinical outcomes of tracheostomy in patients with COVID-19'. Br J Surg 2021; 108:e307. [PMID: 33963833 PMCID: PMC8136019 DOI: 10.1093/bjs/znab167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 04/16/2021] [Indexed: 11/15/2022]
Affiliation(s)
- C Lockhart
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina
| | - I Carboni Bisso
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina.,Intensive Care Unit, Sanatorio Franchin, Argentina.,Intensive Care Unit, Hospital San Antonio, Argentina
| | - A Potenzoni
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina
| | - N Bertoia
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina
| | - M Arias
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina
| | - I F Ceballos
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina
| | - M Las Heras
- Intensive Care Unit, Hospital Italiano de Buenos Aires, Argentina
| |
Collapse
|
11
|
Alvarenga M, Bernardo R, Maciel A, Arias M, Barberini D, Ramos L, Takahira R, Landim-Alvarenga F. Safety of intravenous and topic eye application of canine mesenchymal stem cells secretome. Cytotherapy 2021. [DOI: 10.1016/s1465324921003364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Arias M, Hinsley A, Nogales‐Ascarrunz P, Carvajal‐Bacarreza PJ, Negroes N, Glikman JA, Milner‐Gulland E. Complex interactions between commercial and noncommercial drivers of illegal trade for a threatened felid. Anim Conserv 2021. [DOI: 10.1111/acv.12683] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- M. Arias
- Department of Zoology Zoology Research and Administration Building University of Oxford Oxford UK
| | - A. Hinsley
- WildCRU, Department of Zoology Zoology Research and Administration Building University of Oxford Oxford UK
| | | | - P. J. Carvajal‐Bacarreza
- Colección Boliviana de Fauna Museo de Historia Natural Ministerio de Medio Ambiente y Agua La Paz Bolivia
| | - N. Negroes
- CESAM and Biology Department Aveiro University Aveiro Portugal
- ACEAA‐Conservación Amazónica La Paz Bolivia
| | - J. A. Glikman
- Instituto de Estudios Sociales Avanzados (IESA‐CSIC) Córdoba Spain
| | - E.J. Milner‐Gulland
- Department of Zoology Zoology Research and Administration Building University of Oxford Oxford UK
| |
Collapse
|
13
|
Moreno V, Sepulveda JM, Vieito M, Hernández-Guerrero T, Doger B, Saavedra O, Ferrero O, Sarmiento R, Arias M, De Alvaro J, Di Martino J, Zuraek M, Sanchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Hanna B, Nikolova Z, Braña I. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Ann Oncol 2020; 31:780-788. [PMID: 32240793 DOI: 10.1016/j.annonc.2020.03.294] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 02/13/2020] [Accepted: 03/18/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes involved in oncogenesis. CC-90010 is a novel, oral, reversible, small-molecule BET inhibitor. PATIENTS AND METHODS CC-90010-ST-001 (NCT03220347; 2015-004371-79) is a phase I dose-escalation and expansion study of CC-90010 in patients with advanced or unresectable solid tumors and relapsed/refractory (R/R) non-Hodgkin's lymphoma (NHL). We report results from the dose escalation phase, which explored 11 dose levels and four dosing schedules, two weekly (2 days on/5 days off; 3 days on/4 days off), one biweekly (3 days on/11 days off), and one monthly (4 days on/24 days off). The primary objectives were to determine the safety, maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) and schedule. Secondary objectives were to evaluate signals of early antitumor activity, pharmacokinetics, and pharmacodynamics. RESULTS This study enrolled 69 patients, 67 with solid tumors and two with diffuse large B-cell lymphoma (DLBCL). The median age was 57 years (range, 21-80) and the median number of prior regimens was four (range, 1-9). Treatment-related adverse events (TRAEs) were mostly mild and manageable; grade 3/4 TRAEs reported in more than two patients were thrombocytopenia (13%), anemia, and fatigue (4% each). Six patients had dose-limiting toxicities. MTDs were 15 mg (2 days on/5 days off), 30 mg (3 days on/11 days off), and 45 mg (4 days on/24 days off). The RP2D and schedule selected for expansion was 45 mg (4 days on/24 days off). As of 8 October 2019, one patient with grade 2 astrocytoma achieved a complete response, one patient with endometrial carcinoma had a partial response, and six patients had prolonged stable disease ≥11 months. CONCLUSIONS CC-90010 is well tolerated, with single-agent activity in patients with heavily pretreated, advanced solid tumors.
Collapse
Affiliation(s)
- V Moreno
- START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain.
| | - J M Sepulveda
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Vieito
- Department of Gene Expression and Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - B Doger
- START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain
| | - O Saavedra
- Department of Gene Expression and Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - O Ferrero
- START Madrid-FJD, Hospital Fundación Jimenez Diaz, Madrid, Spain
| | - R Sarmiento
- Celgene Institute for Translational Research Europe, a Bristol Myers Squibb Company, Seville, Spain
| | - M Arias
- Celgene Institute for Translational Research Europe, a Bristol Myers Squibb Company, Seville, Spain
| | - J De Alvaro
- Celgene Institute for Translational Research Europe, a Bristol Myers Squibb Company, Seville, Spain
| | | | - M Zuraek
- Bristol Myers Squibb, San Francisco, USA
| | - T Sanchez-Pérez
- Celgene Institute for Translational Research Europe, a Bristol Myers Squibb Company, Seville, Spain
| | - I Aronchik
- Bristol Myers Squibb, San Francisco, USA
| | | | - M Lamba
- Bristol Myers Squibb, Summit, USA
| | - B Hanna
- Bristol Myers Squibb, Summit, USA
| | - Z Nikolova
- Celgene Institute for Translational Research Europe, a Bristol Myers Squibb Company, Seville, Spain
| | - I Braña
- Department of Gene Expression and Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| |
Collapse
|
14
|
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Castillo Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, Dematte D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Fernández Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Gómez Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, León Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Maturana Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Rodríguez Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Salinas Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Silva Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8:453-460. [PMID: 32145830 DOI: 10.1016/s2213-2600(20)30036-9] [Citation(s) in RCA: 263] [Impact Index Per Article: 65.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 01/06/2020] [Accepted: 01/16/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. METHODS The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. FINDINGS Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI -8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [-31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population. INTERPRETATION The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis. FUNDING Boehringer Ingelheim.
Collapse
Affiliation(s)
- Athol U Wells
- National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Kevin R Flaherty
- Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Kevin K Brown
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - Yoshikazu Inoue
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
| | - Anand Devaraj
- Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College, London, UK
| | - Luca Richeldi
- Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Teng Moua
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, USA
| | - Bruno Crestani
- Université de Paris, Inserm U1152, APHP, Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires rares, Paris, France
| | - Wim A Wuyts
- Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
| | | | - Manuel Quaresma
- Boehringer Ingelheim International, Ingelheim am Rhein, Germany
| | | | | | - Martin Kolb
- McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hollebecque A, de Bono J, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, De Braud F, López-Brea M, Martin-Romano P, Baudin E, Arias M, De Alvaro J, Parra-Palau J, Sánchez-Pérez T, Aronchik I, Filvaroff E, Lamba M, Nikolova Z. 18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.01.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
16
|
Hollebecque A, de Bono J, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, De Braud F, López-Brea M, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau J, Sánchez Pérez T, Filvaroff E, Lamba M, Nikolova Z. Phase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz256.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Arias M, Díaz A, Muñoz A, Valenzuela N, Nasabun Flores V. PCV13 EFECTIVIDAD DEL CATETER VENOSO DE INSERCION CENTRAL VS EL CATETER VENOSO CENTRAL DE INSERCION PERIFERICA EN EL TRATAMIENTO DE PACIENTES EN LA UNIDAD DE CUIDADOS INTENSIVOS. Value Health Reg Issues 2019. [DOI: 10.1016/j.vhri.2019.08.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Gallardo C, Fernández-Pinero J, Arias M. African swine fever (ASF) diagnosis, an essential tool in the epidemiological investigation. Virus Res 2019; 271:197676. [PMID: 31362027 DOI: 10.1016/j.virusres.2019.197676] [Citation(s) in RCA: 78] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Revised: 07/24/2019] [Accepted: 07/25/2019] [Indexed: 11/17/2022]
Abstract
Since there is no vaccine available, prevention, control, and eradication of African swine fever (ASF) is based on the implementation of appropriated surveillance and strict sanitary measures. Success of surveillance activities depends on the availability of the most appropriate diagnostic tests. Although a number of good validated ASF diagnostic techniques are available, the interpretation of the ASF diagnostic results can be complex. The reasons lie in the complexity of the epidemiology with different scenarios, as well as in the characteristics of the viruses circulating giving rise to a wide range of clinical forms of ASF. This review provides guidance for an accurate interpretation of ASF diagnostic results linked to the different clinical presentations ranging from per-acute to chronic disease, including apparently asymptomatic infections.
Collapse
Affiliation(s)
- C Gallardo
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, 28130, Madrid, Spain.
| | - J Fernández-Pinero
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, 28130, Madrid, Spain
| | - M Arias
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, INIA-CISA, Valdeolmos, 28130, Madrid, Spain
| |
Collapse
|
19
|
Arias M. Keys to overcoming the challenge of diagnosing autosomal recessive spinocerebellar ataxia. Neurología (English Edition) 2019. [DOI: 10.1016/j.nrleng.2018.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
20
|
Medina AL, Garcia A, Perez C, Montesinos P, Nieto I, Nieto A, Ochagavia V, Arias M, Salvador F, Salgado M, Muñoz V. EP-2024 Assessment of ADC value when comparing two methods to reduce geometrical distortion in DWMRI. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32444-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Arias M. Neurology of ecstatic religious and similar experiences: ecstatic, orgasmic, and musicogenic seizures. Stendhal syndrome and autoscopic phenomena. Neurología (English Edition) 2019. [DOI: 10.1016/j.nrleng.2016.04.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
Alessandro F, Scarcello A, Basantes Valverde MD, Coello Fiallos DC, Osman SM, Cupolillo A, Arias M, Arias de Fuentes O, De Luca G, Aloise A, Curcio E, Nicotra G, Spinella C, Caputi LS. Selective synthesis of turbostratic polyhedral carbon nano-onions by arc discharge in water. Nanotechnology 2018; 29:325601. [PMID: 29761791 DOI: 10.1088/1361-6528/aac4ca] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Carbon nano-onions (CNOs), in their spherical or polyhedral forms, represent an important class of nanomaterials, due to their peculiar physical and electrochemical properties. Among the different methods of production, arc discharge between graphite electrodes sustained by deionized water is one of the most promising to obtain good quality CNOs in gram quantities. We applied the method with the aim to optimize the production of CNOs, using an innovative experimental arrangement. The discharges generate dispersed nanomaterials and a black hard cathodic deposit, which were studied by transmission electron microscopy-high-resolution TEM, scanning electron microscopy, Raman, thermogravimetric analysis and energy-dispersive x-ray spectroscopy. A simple mechanical grinding of the deposits permitted us to obtain turbostratic polyhedral CNOs that exhibited higher stability towards burning in air, compared to CNOs found in water. We propose a mechanism for the formation of the CNOs present in the deposit, in which the crystallization is driven by a strong temperature gradient existing close to the cathode surface at the beginning of the process, and subsequently close to the deposit surface whenever it is growing.
Collapse
Affiliation(s)
- F Alessandro
- Surface Nanoscience Group, Department of Physics, University of Calabria, Via P. Bucci Cubo 31C, I-87036 Rende, Cosenza, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Coello-Fiallos D, Cazzanelli E, Tavolaro A, Tavolaro P, Arias M, Caputi LS. Cresyl Violet Adsorption on Sonicated Graphite Oxide. J Nanosci Nanotechnol 2018; 18:3006-3011. [PMID: 29442987 DOI: 10.1166/jnn.2018.14337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
We present a study of adsorption of Cresyl Violet (CV) in aqueous solution on sonicated Graphite Oxide (sGO). For comparison, we also show adsorption results of Methylene Blue (MB) and Acridine Orange (AO) performed in the same conditions. The adsorbent was synthesized by the Tour's method followed by washing in water and ethanol and sonication, without any reduction, and studied by Raman, IR, UV-Vis, SEM and TEM techniques. Our results show that adsorption fits the pseudosecond order model for the three dyes, and that the adsorption quantity for CV is 125.0 mg g-1, while for MB and AO is 123.3 and 94.6 mg g-1 respectively.
Collapse
Affiliation(s)
- D Coello-Fiallos
- Surface Nanoscience Group, Department of Physics, University of Calabria, 87036 Rende, Cosenza, Italy
| | - E Cazzanelli
- Department of Physics, University of Calabria, 87036 Rende, Cosenza, Italy
| | - A Tavolaro
- Research Institute on Membrane Technology (ITM-CNR), University of Calabria, 87036 Rende, Cosenza, Italy
| | - P Tavolaro
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Cosenza, Italy Á
| | - M Arias
- Laboratorio de Nanotecnología, Área de Ciencias Basicas y Ambientales, Instituto Tecnológico de Santo Domingo, Av. Los Próceres, Santo Domingo, 10602, República Dominicana
| | - L S Caputi
- Surface Nanoscience Group, Department of Physics, University of Calabria, 87036 Rende, Cosenza, Italy
| |
Collapse
|
24
|
Arias M, de Francisco A, Ruiz L, Val F, Gonzalez M, Zubimendi A. Acquired Renal Cystic Disease and Renal Adenocarcinoma in a Long Term Renal Transplant Patient. Int J Artif Organs 2018. [DOI: 10.1177/039139888600900413] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- M. Arias
- Departments of Nephrology and Pathology Hospital Nacional Valdecilla Santander 39008 Spain
| | - A.L.M. de Francisco
- Departments of Nephrology and Pathology Hospital Nacional Valdecilla Santander 39008 Spain
| | - L. Ruiz
- Departments of Nephrology and Pathology Hospital Nacional Valdecilla Santander 39008 Spain
| | - F. Val
- Departments of Nephrology and Pathology Hospital Nacional Valdecilla Santander 39008 Spain
| | - M. Gonzalez
- Departments of Nephrology and Pathology Hospital Nacional Valdecilla Santander 39008 Spain
| | - A. Zubimendi
- Departments of Nephrology and Pathology Hospital Nacional Valdecilla Santander 39008 Spain
| |
Collapse
|
25
|
Abstract
Summary
Background: Cost-effectiveness analysis (CEA) is used increasingly in medicine to determine whether the health benefit of an intervention is worth the economic cost. Decision trees, the standard decision modeling technique for non-temporal domains, can only perform CEA for very small problems.
Objective: To develop a method for CEA in problems involving several dozen variables.
Methods: We explain how to build influence diagrams (IDs) that explicitly represent cost and effectiveness. We propose an algorithm for evaluating cost-effectiveness IDs directly, i.e., without expanding an equivalent decision tree.
Results: The evaluation of an ID returns a set of intervals for the willingness to pay – separated by cost-effectiveness thresholds – and, for each interval, the cost, the effectiveness, and the optimal intervention. The algorithm that evaluates the ID directly is in general much more efficient than the brute-force method, which is in turn more efficient than the expansion of an equivalent decision tree. Using OpenMarkov, an open-source software tool that implements this algorithm, we have been able to perform CEAs on several IDs whose equivalent decision trees contain millions of branches.
Conclusion: IDs can perform CEA on large problems that cannot be analyzed with decision trees.
Collapse
|
26
|
|
27
|
Arias M, Jurado C, Gallardo C, Fernández-Pinero J, Sánchez-Vizcaíno JM. Gaps in African swine fever: Analysis and priorities. Transbound Emerg Dis 2017; 65 Suppl 1:235-247. [PMID: 28941208 DOI: 10.1111/tbed.12695] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Indexed: 11/29/2022]
Abstract
African swine fever (ASF) causes greater sanitary, social and economic impacts on swine herds than many other swine diseases. Although ASF was first described in 1921 and it has affected more than fifty countries in Africa, Europe and South America, several key issues about its pathogenesis, immune evasion and epidemiology remain uncertain. This article reviews the main characteristics of the causative virus, its molecular epidemiology, natural hosts, clinical features, epidemiology and control worldwide. It also identifies and prioritizes gaps in ASF from a horizontal point of view encompassing fields including molecular biology, epidemiology, prevention, diagnosis and vaccine development. The purpose of this review is to promote ASF research and enhance its control.
Collapse
Affiliation(s)
- M Arias
- Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain
| | - C Jurado
- VISAVET Center and Animal Health Department, Universidad Complutense de Madrid, Madrid, Spain
| | - C Gallardo
- Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain
| | | | - J M Sánchez-Vizcaíno
- VISAVET Center and Animal Health Department, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
28
|
Sosa M, Arias M. A-70Neurological and Psychological Effects with Chikungunya Infectious Disease: A Systematic Literature Review. Arch Clin Neuropsychol 2017. [DOI: 10.1093/arclin/acx076.70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
29
|
|
30
|
Irure J, López-Hoyos M, Rodrigo E, Gómez-Román J, Ruiz JC, Arias M, San Segundo D. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies? Transplant Proc 2017; 48:2888-2890. [PMID: 27932099 DOI: 10.1016/j.transproceed.2016.09.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/13/2016] [Accepted: 09/01/2016] [Indexed: 10/20/2022]
Abstract
INTRODUCTION The definition of antibody-mediated rejection (AMR) is based on serologic (presence and/or development of donor-specific anti-HLA antibodies [DSAs]) and histologic (C4d deposition and endothelial damage) criteria. However, several cases of AMR have been described without C4d deposition, and other cases of histologic AMR without DSAs, which could be driven by other non-HLA alloantibodies such as anti-MICA or anti-angiotensin II type I receptor (AT1R). Here we studied clinical and histologic humoral rejection in kidney transplant recipients without evidence of anti-HLA antibodies. MATERIALS AND METHODS Fifteen kidney transplant recipients with AMR defined as C4d+ and/or histologic g+ptc without anti-HLA antibodies in screening test were studied. Sera at the moment of biopsy and 2 months earlier were studied for anti-HLA antibodies by Luminex, in neat, diluted 1/160, and sera after treatment with dithiothreitol (DTT) and confirmed by single-antigen test. The anti-AT1R was measured by enzyme-linked immunosorbent assay. RESULTS A lack of anti-HLA and MICA antibodies was confirmed after anti-HLA screening test in all conditions (neat, diluted, and DTT-treated) and de novo development of AT1R antibodies was ruled out. Nevertheless, after single-antigen test, 3 patients were identified with a weak reaction against class I antigen and another 4 patients against class II antigen. Due to the lack of locus-C typing in the donors, the DSA assignment cannot be confirmed, whereas anti-HLA class II antigens were DSA. CONCLUSIONS A low sensitivity in the screening of anti-HLA antibody testing was observed. Our results suggest performing single-antigen test in seronegative patients with clinical humoral rejection after screening to confirm the presence of DSA.
Collapse
Affiliation(s)
- J Irure
- Immunology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain
| | - M López-Hoyos
- Immunology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain
| | - E Rodrigo
- Nephrology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain
| | - J Gómez-Román
- Pathology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain
| | - J C Ruiz
- Nephrology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain
| | - M Arias
- Nephrology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain
| | - D San Segundo
- Immunology Service, Marqués de Valdecilla Hospital-IDIVAL, Santander, Spain.
| |
Collapse
|
31
|
Sango C, Merino D, San Segundo D, Rodrigo E, Lopez-Hoyos M, Benito A, Ángeles Ramos M, Gómez-Román J, Arias M. B-Cell-Activating Factor Levels Are Associated With Antibody-Mediated Histological Damage in Kidney Transplantation. Transplant Proc 2017; 48:2910-2912. [PMID: 27932105 DOI: 10.1016/j.transproceed.2016.09.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 08/19/2016] [Accepted: 09/02/2016] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Along with death engraftment, in recent years, antibody-mediated damage has been identified as the leading cause of loss of kidney transplants. Despite the recognition of the role of the B-lymphocyte subpopulation in the development of both tolerance and rejection, little is known about the trigger mechanisms and effectors of this humoral response. BACKGROUND We analyzed the relationship between B lymphocyte subpopulations and levels of B-cell-activating factor (BAFF) with the histological findings in biopsies of renal transplantation. MATERIAL AND METHODS We selected 35 patients whose kidney transplant biopsy was performed between January and November 2015. The biopsy specimens were classified according to Banff criteria. At the moment of the biopsy BAFF levels and B-lymphocyte subpopulations in blood were measured using enzyme-linked immunosorbent assay (ELISA) and using flow cytometry, respectively. RESULTS Mean BAFF levels were 493 ± 245 pg/mL. The median performance of biopsy post-transplantation was 12.9 (11.7-23.9) months. BAFF levels correlated with pretransplantation antibodies (r = 0.523; P = .002) but not with kidney function. In biopsies performed more than 1 year after transplantation BAFF levels correlated with the severity of chronic glomerular (cg) involvement (r = 0.625; P = .003). Histological variables related to antibody-mediated injury selected by principal component analysis (glomerulitis, peritubular capillary, and chronic glomerulopathy) related to BAFF levels (B factor, 116; 95% confidence interval [CI], 12-220; P = .029). Biopsy specimens with transplant glomerulopathy (TG) showed lower levels of circulating naive CD19 + subpopulation, IgD+, and CD27- (32.7 ± 28.1 vs 87.9 ± 79.1; P = .017) compared with biopsy specimens without TG. CONCLUSIONS Elevated levels of BAFF are associated with increased presence and severity of TG and a set of variables related to antibody-mediated histological damage. TG is associated with changes in circulating B-lymphocyte subpopulations that could contribute to its pathogenesis.
Collapse
Affiliation(s)
- C Sango
- Department of Nephrology, Valdecilla Hospital, University of Cantabria, Santander, Spain.
| | - D Merino
- Autoimmunity and Transplantation Laboratory, Instituto de investigación Marqués de Valdecilla - Marqués de Valdecilla Research Institute, Santander, Spain
| | - D San Segundo
- Department of Immunology, Valdecilla Hospital, Santander, Spain
| | - E Rodrigo
- Department of Nephrology, Valdecilla Hospital, University of Cantabria, Santander, Spain
| | - M Lopez-Hoyos
- Department of Immunology, Valdecilla Hospital, Santander, Spain
| | - A Benito
- Autoimmunity and Transplantation Laboratory, Instituto de investigación Marqués de Valdecilla - Marqués de Valdecilla Research Institute, Santander, Spain
| | - M Ángeles Ramos
- Autoimmunity and Transplantation Laboratory, Instituto de investigación Marqués de Valdecilla - Marqués de Valdecilla Research Institute, Santander, Spain
| | - J Gómez-Román
- Department of Anatomic Pathology, Valdecilla Hospital, Santander, Spain
| | - M Arias
- Department of Nephrology, Valdecilla Hospital, University of Cantabria, Santander, Spain
| |
Collapse
|
32
|
Abstract
Introduction Multiple sclerosis (MS) is the most common central nervous system disease in young adults, and one of the leading causes of disability in this age group. Objectives To establish the prevalence and incidence of MS in Santiago de Compostela (Spain). Material and methods We performed a prospective, case-finding study on >90188 inhabitants, from 1 January 1998 to 15 September 2003, selected as day of prevalence. Sources of information were the University Clinical Hospital of Santiago, the hospitals and private clinics of the city, rehabilitators, pediatricians, ophthalmologists, psychiatrists, neurosurgeons, specialists in internal medicine, primary care physicians, association of patients of MS, social services and nongovernmental and religious associations. Informative days were programmed for the susceptible population, and campaigns were carried out in the media. All patients with Poser diagnostic criteria for MS, on the census of Santiago de Compostela as of 15 September 2003, were included in the study. Results On the day of prevalence, 71 patients with MS were registered on the census of Santiago de Compostela, therefore, the prevalence was 79 cases per 100000 inhabitants. The incidence of the disease in the study period was 5.3 cases per 100000 inhabitants and year. Conclusions The prevalence and incidence rates of MS found in Santiago de Compostela are the highest reported, to date, in Spain. Multiple Sclerosis 2007; 13: 262–264. http://msj.sagepub.com
Collapse
Affiliation(s)
- B Ares
- Department of Neurology, Hospital Clínico Universitario, Institute of Neurological Sciences of Galicia P Barrié de la Maza, Santiago de Compostela, Spain.
| | | | | | | | | | | |
Collapse
|
33
|
Cheuquemán C, Loren P, Arias M, Risopatrón J, Felmer R, Álvarez J, Mogas T, Sánchez R. Decrease in bovine in vitro embryo production efficiency during winter season in a warm-summer Mediterranean climate. Andrologia 2016; 49. [PMID: 28000967 DOI: 10.1111/and.12758] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/04/2016] [Indexed: 11/30/2022] Open
Abstract
Retrospective analysis of monthly embryo production from December 2011 to May 2015 and its correlation with meteorological data in our geographic zone was made. We had observed that in certain time of the year, in vitro blastocyst production decreases. Accordingly, was examined the association between blastocyst production and climatological parameters. Cleavage rates correlate positively with blastocyst rates (p < .05). Significant differences in cleavage rates between autumn and summer (79.8%; 71.5%), and between winter and autumn (71.8%; 79.8%), were found. Blastocyst production had lower efficiency in June (9 ± 12%) and July (4.9 ± 5.7%), which coincides with winter season. In contrast, higher embryo production was obtained in February (22.2 ± 9.7%), March (22.9 ± 14%) and September (25.2 ± 6.6%), which coincides with autumn and spring season. Similarly, embryo production correlates with meteorological parameters: blastocyst production positively correlates with sunshine hours, maximum temperature and average temperature. Similarly, blastocyst production inversely correlates with total precipitation and days >1 mm precipitation (p < .05). There is a significant decrease in bovine in vitro embryo production efficiency during winter season in our warm-summer Mediterranean climate zone. It remains to be investigated the direct effect of environmental factors on oocyte quality and its impact on in vitro production efficiency.
Collapse
Affiliation(s)
- C Cheuquemán
- Facultad de Medicina, Centro de Biotecnología de la Reproducción (BIOREN-CEBIOR), Universidad de La Frontera, Temuco, Chile
| | - P Loren
- Facultad de Medicina, Centro de Biotecnología de la Reproducción (BIOREN-CEBIOR), Universidad de La Frontera, Temuco, Chile
| | - M Arias
- Facultad de Medicina, Centro de Biotecnología de la Reproducción (BIOREN-CEBIOR), Universidad de La Frontera, Temuco, Chile
| | - J Risopatrón
- Facultad de Medicina, Centro de Biotecnología de la Reproducción (BIOREN-CEBIOR), Universidad de La Frontera, Temuco, Chile.,Departamento de Ciencias Básicas, Universidad de La Frontera, Temuco, Chile
| | - R Felmer
- Facultad de Medicina, Centro de Biotecnología de la Reproducción (BIOREN-CEBIOR), Universidad de La Frontera, Temuco, Chile.,Departamento de Ciencias Agronómicas y Recursos Naturales, Facultad de Ciencias Agropecuarias y Forestales, Universidad de La Frontera, Temuco, Chile
| | | | - T Mogas
- Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - R Sánchez
- Facultad de Medicina, Centro de Biotecnología de la Reproducción (BIOREN-CEBIOR), Universidad de La Frontera, Temuco, Chile.,Departamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile
| |
Collapse
|
34
|
Uzal M, Saadi J, Arias M, Solchaga T, Viglierchio V, Gogorza S. Rokitansky-Küster-Hauser Syndrome: Surgical Treatement – Hospital Italiano de Buenos Aires. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Sastre P, Gallardo C, Monedero A, Ruiz T, Arias M, Sanz A, Rueda P. Development of a novel lateral flow assay for detection of African swine fever in blood. BMC Vet Res 2016; 12:206. [PMID: 27633968 PMCID: PMC5025629 DOI: 10.1186/s12917-016-0831-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Accepted: 09/06/2016] [Indexed: 11/21/2022] Open
Abstract
Background African swine fever (ASF) is a viral infectious disease of domestic and wild suids of all breeds and ages, causing a wide range of hemorrhagic syndromes and frequently characterized by high mortality. The disease is endemic in Sub-Saharan Africa and Sardinia. Since 2007, it has also been present in different countries of Eastern Europe, where control measures have not been effective so far. The continued spread poses a serious threat to the swine industry worldwide. In the absence of vaccine, early detection of infected animals is of paramount importance for control of the outbreak, to prevent the transmission of the virus to healthy animals and subsequent spreading of the disease. Current laboratory diagnosis is mainly based on virological methods (antigen and genome detection) and serodiagnosis. Results In the present work, a Lateral Flow Assay (LFA) for antigen detection has been developed and evaluated. The test is based on the use of a MAb against VP72 protein of ASFV, the major viral capsid protein and highly immunogenic. First experiments using VP72 viral and recombinant protein or inactivated culture virus showed promising results with a sensitivity similar to that of a commercially available Antigen-ELISA. Moreover, these strips were tested with blood from experimentally infected pigs and field animals and the results compared with those of PCR and Antigen-ELISA. For the experimentally infected samples, there was an excellent correlation between the LFA and the ELISA, while the PCR always showed to be more sensitive (38 % positive samples by PCR versus 27 % by LFA). The LFA was demonstrated to be positive for animals with circulating virus levels exceeding 104 HAU. With the field samples, once again, the PCR detected more positives than either the Antigen-ELISA or LFA, although here the number of positive samples scored by the LFA exceeded the values obtained with the Antigen-ELISA, showing 60 % positivity vs 48 % for the ELISA. For the two groups of sera, the specificity was close to 100 % indicating that hardly any false positive samples were found. Conclusions The newly developed LFA allows rapid and reliable detection of ASFV, at field and laboratory level, providing a new useful tool for control programs and in situations where laboratory support and skilled personnel are limited.
Collapse
Affiliation(s)
- P Sastre
- Inmunología y Genética Aplicada S. A. (INGENASA), Madrid, Spain.
| | - C Gallardo
- European Union Reference Laboratory for ASF (EURL), Centro de Investigación en Sanidad Animal, INIA, Madrid, Spain
| | - A Monedero
- Inmunología y Genética Aplicada S. A. (INGENASA), Madrid, Spain
| | - T Ruiz
- Inmunología y Genética Aplicada S. A. (INGENASA), Madrid, Spain
| | - M Arias
- European Union Reference Laboratory for ASF (EURL), Centro de Investigación en Sanidad Animal, INIA, Madrid, Spain
| | - A Sanz
- Inmunología y Genética Aplicada S. A. (INGENASA), Madrid, Spain
| | - P Rueda
- Inmunología y Genética Aplicada S. A. (INGENASA), Madrid, Spain
| |
Collapse
|
36
|
Arias JP, Zapata K, Rojano B, Arias M. Effect of light wavelength on cell growth, content of phenolic compounds and antioxidant activity in cell suspension cultures of Thevetia peruviana. J Photochem Photobiol B 2016; 163:87-91. [PMID: 27541569 DOI: 10.1016/j.jphotobiol.2016.08.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Accepted: 08/10/2016] [Indexed: 10/21/2022]
Abstract
Thevetia peruviana (T. peruviana) has been considered as a potentially important plant for industrial and pharmacological application. Among the number of compounds which are produced by T. peruviana, antioxidants and polyphenols are of particular interest due to their benefits on human health. Cell suspension cultures of T. peruviana were established under different conditions: 1) constant illumination (24h/day) at different light wavelengths (red, green, blue, yellow and white), 2) darkness and 3) control (12h/12h: day light/dark) to investigate their biomass, substrate uptake, polyphenols production and oxidizing activity. The results showed biomass concentrations between 17.1g dry weight (DW)/l (green light) and 18.2g DW/l (control) after 13days. The cultures that grew under green light conditions consumed completely all substrates after 10days, while other cultures required at least 13days or more. The total phenolic content was between 7.21 and 9.46mg gallic acid (GA)/g DW for all light conditions. In addition the ferric reducing antioxidant power and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid antioxidant activity ranged from 5.41-6.58mg ascorbic acid (AA)/g DW and 82.93-110.39μmol Trolox/g DW, respectively. Interestingly, the samples which grew under the darkness presented a higher phenolic content and antioxidant capacity when compared to the light conditions. All together, these results demonstrate the extraordinary effect of different lighting conditions on polyphenols production and antioxidant compounds by T. peruviana.
Collapse
Affiliation(s)
- J P Arias
- Escuela de Biociencias, Facultad de Ciencias, Universidad Nacional de Colombia, sede Medellín, Medellín, Antioquia, Colombia.
| | - K Zapata
- Escuela de Biociencias, Facultad de Ciencias, Universidad Nacional de Colombia, sede Medellín, Medellín, Antioquia, Colombia
| | - B Rojano
- Escuela de Biociencias, Facultad de Ciencias, Universidad Nacional de Colombia, sede Medellín, Medellín, Antioquia, Colombia
| | - M Arias
- Escuela de Biociencias, Facultad de Ciencias, Universidad Nacional de Colombia, sede Medellín, Medellín, Antioquia, Colombia
| |
Collapse
|
37
|
Roman-Pena P, Gonzalez-Gomez L, Santin-Amo JM, Arias M, Gelabert-Gonzalez M. [Stenosis of the aqueduct of Sylvius and dilatation of Virchow-Robin spaces]. Rev Neurol 2016; 63:42-43. [PMID: 27345279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Affiliation(s)
- P Roman-Pena
- Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana
| | - L Gonzalez-Gomez
- Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana
| | - J M Santin-Amo
- Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana
| | - M Arias
- Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana
| | - M Gelabert-Gonzalez
- Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana
| |
Collapse
|
38
|
Achenbach JE, Gallardo C, Nieto-Pelegrín E, Rivera-Arroyo B, Degefa-Negi T, Arias M, Jenberie S, Mulisa DD, Gizaw D, Gelaye E, Chibssa TR, Belaye A, Loitsch A, Forsa M, Yami M, Diallo A, Soler A, Lamien CE, Sánchez-Vizcaíno JM. Identification of a New Genotype of African Swine Fever Virus in Domestic Pigs from Ethiopia. Transbound Emerg Dis 2016; 64:1393-1404. [PMID: 27211823 DOI: 10.1111/tbed.12511] [Citation(s) in RCA: 133] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Indexed: 11/29/2022]
Abstract
African swine fever (ASF) is an important emerging transboundary animal disease (TAD), which currently has an impact on many countries in Africa, Eastern Europe, the Caucasus and the Russian Federation. The current situation in Europe shows the ability of the virus to rapidly spread, which stands to threaten the global swine industry. At present, there is no viable vaccine to minimize spread of the disease and stamping out is the main source of control. In February 2011, Ethiopia had reported its first suspected outbreaks of ASF. Genomic analyses of the collected ASF virus (ASFV) strains were undertaken using 23 tissue samples collected from domestic swine in Ethiopia from 2011 to 2014. The analysis of Ethiopian ASFVs partial p72 gene sequence showed the identification of a new genotype, genotype XXIII, that shares a common ancestor with genotypes IX and X, which comprise isolates circulating in Eastern African countries and the Republic of Congo. Analysis of the p54 gene also followed the p72 pattern and the deduced amino acid sequence of the central variable region (CVR) of the B602L gene showed novel tetramer repeats not previously characterized.
Collapse
Affiliation(s)
- J E Achenbach
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - C Gallardo
- European Union Reference Laboratory for ASF: Centro de Investigación en Sanidad Animal, INIA, Madrid, Spain
| | - E Nieto-Pelegrín
- OIE Reference Laboratory for ASF: VISAVET Health Surveillance Centre, Universidad Complutense Madrid, Madrid, Spain.,Animal Health Department, Universidad Complutense Madrid, Madrid, Spain
| | - B Rivera-Arroyo
- OIE Reference Laboratory for ASF: VISAVET Health Surveillance Centre, Universidad Complutense Madrid, Madrid, Spain.,Animal Health Department, Universidad Complutense Madrid, Madrid, Spain
| | | | - M Arias
- European Union Reference Laboratory for ASF: Centro de Investigación en Sanidad Animal, INIA, Madrid, Spain
| | - S Jenberie
- National Veterinary Institute, Debre Ziet, Ethiopia
| | - D D Mulisa
- National Animal Health Diagnostic and Investigation Center (NAHDIC), Sebeta, Ethiopia
| | - D Gizaw
- National Animal Health Diagnostic and Investigation Center (NAHDIC), Sebeta, Ethiopia
| | - E Gelaye
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.,National Veterinary Institute, Debre Ziet, Ethiopia
| | - T R Chibssa
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.,National Animal Health Diagnostic and Investigation Center (NAHDIC), Sebeta, Ethiopia
| | - A Belaye
- National Veterinary Institute, Debre Ziet, Ethiopia
| | - A Loitsch
- Institute for Veterinary Disease Control, Austrian Agency for Health and Food Safety, Mödling, Austria
| | - M Forsa
- National Animal Health Diagnostic and Investigation Center (NAHDIC), Sebeta, Ethiopia
| | - M Yami
- National Veterinary Institute, Debre Ziet, Ethiopia
| | - A Diallo
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - A Soler
- European Union Reference Laboratory for ASF: Centro de Investigación en Sanidad Animal, INIA, Madrid, Spain
| | - C E Lamien
- Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - J M Sánchez-Vizcaíno
- OIE Reference Laboratory for ASF: VISAVET Health Surveillance Centre, Universidad Complutense Madrid, Madrid, Spain.,Animal Health Department, Universidad Complutense Madrid, Madrid, Spain
| |
Collapse
|
39
|
Arias M, Chevallier O, Graham S, Gasull-Gimenez A, Fodey T, Cooper K, Crooks S, Danaher M, Elliott C. Metabolomics reveals novel biomarkers of illegal 5-nitromimidazole treatment in pigs. Further evidence of drug toxicity uncovered. Food Chem 2016; 199:876-84. [DOI: 10.1016/j.foodchem.2015.12.075] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 11/08/2015] [Accepted: 12/17/2015] [Indexed: 01/15/2023]
|
40
|
Kislikova M, Seras M, Monfa E, Rodrigo E, Fernandez-Fresnedo G, Ruiz JC, Arias M. Number of antihypertensive drugs at 1 year after kidney transplantation. Transplant Proc 2015; 47:76-7. [PMID: 25645775 DOI: 10.1016/j.transproceed.2014.12.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
High blood pressure (BP) affects up to 90% of kidney transplant recipients and is associated with lower patient and graft survival rates. Kidney Disease/Improving Global Outcomes (KDIGO) guidelines suggest maintaining BP at lower than 130/80 mm Hg. Multidrug therapy is usually required for the control of BP in this population. Our aim was to analyze the number of antihypertensive drugs used in our kidney transplantation population at 1 year after transplantation and their influence on graft and patient outcome. We included 411 deceased-donor kidney transplantation cases; data were obtained from a prospectively maintained institutional database. BP was measured at the outpatient clinic. Approximately 97 patients were not under antihypertensive therapy, whereas 130, 119, 52, and 13 received 1, 2, 3, or 4 antihypertensive drugs, respectively. The number of antihypertensive drugs was significantly related to lower patient survival rates independently of a previous diagnosis of hypertension and diabetes, recipient age and sex and renal function at 1-year. After multivariate linear regression analysis high body mass index, male gender of recipients, donor hypertension, previous acute rejection, and cyclosporine therapy were risk factors independently related to a higher number of antihypertensive drugs. To conclude, the number of antihypertensive drugs is an objective and easy-to-measure marker related to lower patient survival rates. Recipient body mass index, type of calcineurin inhibitor, and acute rejection are modifiable risk factors whose control can help to reduce the number of antihypertensive drugs needed to treat high BP in the kidney transplantation population.
Collapse
Affiliation(s)
- M Kislikova
- Hospital Universitario Marques de Valdecilla, Santander, Spain.
| | - M Seras
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - E Monfa
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - E Rodrigo
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| | | | - J C Ruiz
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - M Arias
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| |
Collapse
|
41
|
|
42
|
Cheuquemán C, Loren P, Arias M, Risopatrón J, Felmer R, Álvarez J, Mogas T, Sánchez R. Effects of short-term exposure of mature oocytes to sodium nitroprusside on in vitro embryo production and gene expression in bovine. Theriogenology 2015; 84:1431-7. [DOI: 10.1016/j.theriogenology.2015.07.031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 07/25/2015] [Accepted: 07/26/2015] [Indexed: 12/13/2022]
|
43
|
García MJ, Jurado F, San Segundo D, López-Hoyos M, Iruzubieta P, Llerena S, Casafont F, Arias M, Puente Á, Crespo J, Fábrega E. Galectin-1 in stable liver transplant recipients. Transplant Proc 2015; 47:93-6. [PMID: 25645780 DOI: 10.1016/j.transproceed.2014.12.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the "Holy Grail" in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients. METHODS Serum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group. RESULTS The concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group. CONCLUSIONS These preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation.
Collapse
Affiliation(s)
- M J García
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - F Jurado
- Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain; Immunology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain
| | - D San Segundo
- Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain; Immunology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain
| | - M López-Hoyos
- Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain; Immunology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain
| | - P Iruzubieta
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - S Llerena
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - F Casafont
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - M Arias
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - Á Puente
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - J Crespo
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain
| | - E Fábrega
- Gastroenterology and Hepatology Unit, University Hospital "Marqués de Valdecilla", Santander, Spain; Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain.
| |
Collapse
|
44
|
Pias-Peleteiro L, Pias-Peleteiro JM, Arias M. [Tropical spastic paraparesis in a non tropical region]. Rev Neurol 2015; 61:357-362. [PMID: 26461129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION Human T-lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a prevalent disease in certain tropical regions endemic for HTLV-1, being a rare entity in areas such as Europe and North America. CASE REPORTS We report two new cases of HAM/TSP in Caucasians, native from Galicia, Spain. Serum and cerebrospinal fluid (CSF) analysis, clinical neurophysiologic studies and brain and spinal cord MRI scans were performed. Both patients presented a progressive chronic myelopathy, evolving to spastic paraparesis; one of them presenting with uveitis, prior to the onset of neurological symptoms. CSF analysis revealed mild lymphocytic pleocytosis and increased protein concentration with positive anti-HTLV-1 antibodies. Polymerase chain reaction was positive for HTLV-1. Oligoclonal bands were not detected. In one of the patients, MRI scans did not reveal abnormalities whilst in the other there was an elongated high intensity lesion at the thoracic spinal cord level, which resolved after treatment. No evidence of peripheral neuropathy was found. Corticosteroids and interferon alpha therapy was started, with moderate functional improvement. A history of unprotected sexual relationships while travelling to HTLV-1 endemic areas was revealed. CONCLUSIONS HTLV-1-associated uveitis may predict HAM/TSP. HAM/TSP is probably an underdiagnosed disease due to the high prevalence of asymptomatic carriers, insidious clinical presentation and low suspicion index in non-endemic regions for HTLV-1. In non-tropical countries, HAM/TSP should not only be suspected in migrants from endemic areas for HTLV-1, but also in patients from communities with a tradition of migration to tropical countries.
Collapse
|
45
|
Gallardo C, Soler A, Nieto R, Sánchez MA, Martins C, Pelayo V, Carrascosa A, Revilla Y, Simón A, Briones V, Sánchez-Vizcaíno JM, Arias M. Experimental Transmission of African Swine Fever (ASF) Low Virulent Isolate NH/P68 by Surviving Pigs. Transbound Emerg Dis 2015; 62:612-22. [PMID: 26432068 DOI: 10.1111/tbed.12431] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Indexed: 11/29/2022]
Abstract
African swine fever (ASF) has persisted in Eastern Europe since 2007, and two endemic zones have been identified in the central and southern parts of the Russian Federation. Moderate- to low-virulent ASF virus isolates are known to circulate in endemic ASF-affected regions. To improve our knowledge of virus transmission in animals recovered from ASF virus infection, an experimental in vivo study was carried out. Four domestic pigs were inoculated with the NH/P68 ASF virus, previously characterized to develop a chronic form of ASF. Two additional in-contact pigs were introduced at 72 days post-inoculation (dpi) in the same box for virus exposure. The inoculated pigs developed a mild form of the disease, and the virus was isolated from tissues in the inoculated pigs up to 99 dpi (pigs were euthanized at 36, 65, 99 and 134 dpi). In-contact pigs showed mild or no clinical signs, but did become seropositive, and a transient viraemia was detected at 28 days post-exposure (dpe), thereby confirming late virus transmission from the inoculated pigs. Virus transmission to in-contact pigs occurred at four weeks post-exposure, over three months after the primary infection. These results highlight the potential role of survivor pigs in disease maintenance and dissemination in areas where moderate- to low-virulent viruses may be circulating undetected. This study will help design better and more effective control programmes to fight against this disease.
Collapse
Affiliation(s)
- C Gallardo
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - A Soler
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - R Nieto
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - M A Sánchez
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - C Martins
- Faculdade Medicina Veterinária, Universidade Técnica Lisboa (FMV-UTL), Lisbon, Portugal
| | - V Pelayo
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - A Carrascosa
- Centro de Biología Molecular Severo Ochoa, Agencia Estatal Consejo Superior Investigaciones Científicas, CSIC-UAM, Madrid, Spain
| | - Y Revilla
- Centro de Biología Molecular Severo Ochoa, Agencia Estatal Consejo Superior Investigaciones Científicas, CSIC-UAM, Madrid, Spain
| | - A Simón
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - V Briones
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| | - J M Sánchez-Vizcaíno
- VISAVET, Dpto. Sanidad Animal, Facultad Veterinaria, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - M Arias
- European Union Reference Laboratory for African Swine Fever, Centro de Investigación en Sanidad Animal, INIA-CISA, Madrid, Spain
| |
Collapse
|
46
|
Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Bednarek-Skublewska A, Dulawa J, Frantzen L, Ferrari JN, del Castillo D, Bernat AG, Hegbrant J, Wollheim C, Gargano L, Bots CP, Strippoli GF, Raña S, Serrano M, Claros S, Arias M, Petracci L, Arana M, De Rosa P, Gutierrez A, Simon M, Vergara V, Tosi M, Cernadas M, Vilamajó I, Gravac D, Paulón M, Penayo L, Carrizo G, Ghiani M, Perez G, Da Cruz O, Galarce D, Gravielle M, Vescovo E, Paparone R, Mato Mira C, Mojico E, Hermida O, Florio D, Yucoswky M, Labonia W, Rubio D, Di Napoli G, Fernandez A, Altman H, Rodriguez J, Serrano S, Valle G, Lobos M, Acosta V, Corpacci G, Jofre M, Gianoni L, Chiesura G, Capdevila M, Montenegro J, Bequi J, Dayer J, Gómez A, Calderón C, Abrego E, Cechín C, García J, Corral J, Natiello M, Coronel A, Muñiz M, Muñiz V, Bonelli A, Sanchez F, Maestre S, Olivera S, Camargo M, Avalos V, Geandet E, Canteli M, Escobar A, Sena E, Tirado S, Peñalba A, Neme G, Cisneros M, Oliszewski R, Nascar V, Daud M, Mansilla S, Paredes Álvarez A, Gamín L, Arijón M, Coombes M, Zapata M, Boriceanu C, Frantzen-Trendel S, Albert K, Csaszar I, Kiss E, Kosa D, Orosz A, Redl J, Kovacs L, Varga E, Szabo M, Magyar K, Kriza G, Zajko E, Bereczki A, Csikos J, Kuti A, Mike A, Steiner K, Nemeth E, Tolnai K, Toth A, Vinczene J, Szummer S, Tanyi E, Toth R, Szilvia M, Dambrosio N, Paparella G, Sambati M, Donatelli C, Pedone F, Cagnazzo V, Antinoro R, Torsello F, Saturno C, Giannoccaro G, Maldera S, Boccia E, Mantuano M, Di Toro Mammarella R, Meconizzi M, Steri P, Riccardi C, Flammini A, Moscardelli L, Murgo M, San Filippo N, Pagano S, Marino G, Montalto G, Cantarella S, Salamone B, Randazzo G, Rallo D, Maniscalco A, Fici M, Lupo A, Pellegrino P, Fichera R, D’Angelo A, Falsitta N, Bochenska-Nowacka E, Jaroszynski A, Drabik J, Birecka M, Daniewska D, Drobisz M, Doskocz K, Wyrwicz G, Inchaustegui L, Outerelo C, Sousa Mendes D, Mendes A, Lopes J, Barbas J, Madeira C, Fortes A, Vizinho R, Cortesão A, Almeida E, Bernat A, De la Torre B, Lopez A, Martín J, Cuesta G, Rodriguez R, Ros F, Garcia M, Orero E, Ros E, Caetano A, MacGregor K, Santos M, Silva Pinheiro S, Martins L, Leitão D, Izidoro C, Bava G, Bora A, Gorena H, Calderón T, Dupuy R, Alonso N, Siciliano V, Frantzen-Trendel S, Nagy K, Bajusz Ö, Pinke I, Decsi G, Gyergyoi L, Jobba Z, Zalai Z, Zsedenyi Á, Kiss G, Pinter M, Kereszturi M, Petruzzi M, De Benedittis M, Szkutnik J, Sieczkarek J, Capelo A, Garcia Gallart M, Mendieta C. Dental Health and Mortality in People With End-Stage Kidney Disease Treated With Hemodialysis: A Multinational Cohort Study. Am J Kidney Dis 2015; 66:666-76. [DOI: 10.1053/j.ajkd.2015.04.051] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 04/29/2015] [Indexed: 01/28/2023]
|
47
|
Pescador M, Ramos M, Arias M, Gómez-Alamillo C, Sánchez-Barba M, Quiros Y, Blanco-Gozalo V, Pieto M, Vicente-Vicente L, Casanova A, López-Hernández F, Morales A. Biomarkers for the prediction of acute kidney injury: Is canonical biplot analyses a useful tool? Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Chernesky M, Arias M, Jang D, Gilchrist J, Li J, Smieja M. P07.18 Ease and comfort of a novel herswab tmvaginal self-sampling device for the detection of sexually transmitted infections. Br J Vener Dis 2015. [DOI: 10.1136/sextrans-2015-052270.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Gallardo C, Nieto R, Soler A, Pelayo V, Fernández-Pinero J, Markowska-Daniel I, Pridotkas G, Nurmoja I, Granta R, Simón A, Pérez C, Martín E, Fernández-Pacheco P, Arias M. Assessment of African Swine Fever Diagnostic Techniques as a Response to the Epidemic Outbreaks in Eastern European Union Countries: How To Improve Surveillance and Control Programs. J Clin Microbiol 2015; 53:2555-65. [PMID: 26041901 PMCID: PMC4508403 DOI: 10.1128/jcm.00857-15] [Citation(s) in RCA: 108] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2015] [Accepted: 05/22/2015] [Indexed: 11/20/2022] Open
Abstract
This study represents a complete comparative analysis of the most widely used African swine fever (ASF) diagnostic techniques in the European Union (EU) using field and experimental samples from animals infected with genotype II ASF virus (ASFV) isolates circulating in Europe. To detect ASFV, three different PCRs were evaluated in parallel using 785 field and experimental samples. The results showed almost perfect agreement between the Universal ProbeLibrary (UPL-PCR) and the real-time (κ = 0.94 [95% confidence interval {CI}, 0.91 to 0.97]) and conventional (κ = 0.88 [95% CI, 0.83 to 0.92]) World Organisation for Animal Health (OIE)-prescribed PCRs. The UPL-PCR had greater diagnostic sensitivity for detecting survivors and allows earlier detection of the disease. Compared to the commercial antigen enzyme-linked immunosorbent assay (ELISA), good-to-moderate agreement (κ = 0.67 [95% CI, 0.58 to 0.76]) was obtained, with a sensitivity of 77.2% in the commercial test. For ASF antibody detection, five serological methods were tested, including three commercial ELISAs, the OIE-ELISA, and the confirmatory immunoperoxidase test (IPT). Greater sensitivity was obtained with the IPT than with the ELISAs, since the IPT was able to detect ASF antibodies at an earlier point in the serological response, when few antibodies are present. The analysis of the exudate tissues from dead wild boars showed that IPT might be a useful serological tool for determining whether or not animals had been exposed to virus infection, regardless of whether antibodies were present. In conclusion, the UPL-PCR in combination with the IPT was the most trustworthy method for detecting ASF during the epidemic outbreaks affecting EU countries in 2014. The use of the most appropriate diagnostic tools is critical when implementing effective control programs.
Collapse
Affiliation(s)
- C Gallardo
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - R Nieto
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - A Soler
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - V Pelayo
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - J Fernández-Pinero
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | | | - G Pridotkas
- National Food and Veterinary Risk Assessment Institute, Vilnius, Lithuania
| | - I Nurmoja
- Estonian Veterinary and Food Laboratory, Tartu, Estonia
| | - R Granta
- Institute of Food Safety, Animal Health and Environment BIOR, Riga, Latvia
| | - A Simón
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - C Pérez
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - E Martín
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - P Fernández-Pacheco
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| | - M Arias
- European Union Reference Laboratory for African Swine Fever (EURL), Centro de Investigación en Sanidad Animal, CISA/INIA, Valdeolmos, Madrid, Spain
| |
Collapse
|
50
|
Palmou N, Calvo-Río V, Loricera J, Hernández J, Mata C, Martín L, Ortíz-Sanjuán F, Άlvarez L, González-Vela M, González-Lamuño D, Fernández-Llaca H, González-Lόpez M, Armesto S, Arias M, González-Gay M, Blanco R. FRI0246 Relapses and Predictive Factors in Henoch-Schönlein Purpura. Study of 417 Patients. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|